GLENMARK PHARMACEUTICALS LTD. - 532296 - Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024
Enclosed herewith certificate from Practicing Company Secretary under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended 31st March, 2024
Buy Glenmark Pharmaceuticals; target of Rs 1266: KR Choksey
KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1266 in its research report dated April 05, 2024. GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024
Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended 31st March, 2024 GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Retirement
Intimation of retirement of Independent Directors GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
With reference to the subject mentioned above, kindly find enclosed rating research update issued by CRISIL Ratings for your reference. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
With reference to the subject mentioned above, kindly find enclosed rating research update issued by S&P Global ratings for your reference. Request you to kindly take the same on record. GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Pursuant To Regulation 30(7) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure pursuant to Regulation 30(7) of SEBI (LODR) Regulations, 2015 is attached. GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Pursuant To Regulation 30(7) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure pursuant to Regulation 30(7) of SEBI (LODR) Regulations, 2015 is attached. Request you to please ignore the previous earlier letter. GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Pursuant To Regulation 30(7) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure pursuant to Regulation 30(7) of the SEBI LODR Regulations 2015 is attached.
Accumulate Glenmark Pharmaceuticals; target of Rs 984: KR Choksey
KR Choksey recommended Accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 984 in its research report dated February 22, 2024.